CTIS2024-514962-38-00招募中1 期
Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors - BNT211-01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Each patient enrolled in the trial must have CLDN6-positive tumor regardless of tumor histology defined as = 50% of tumor cells expressing = 2+ CLDN6 protein using a semi-quantitative immunohistochemistry (IHC) assay in a central laboratory for specific detection of CLDN6 protein expression in formalin-fixed, paraffin-embedded (FFPE) neoplastic tissues., Must have adequate hematologic function at screening as defined in the protocol., Must have adequate hepatic function at screening as defined in the protocol., Must have adequate renal function at screening as defined in the protocol., Must be able to attend trial visits as required by the protocol., Women of childbearing potential (WOCBP) must have a negative serum (beta-human chorionic gonadotropin) test/value at screening. Patients who are post-menopausal or permanently sterilized can be considered as not having reproductive potential., WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial and thereafter., WOCBP and men that are sexually active with a WOCBP and have not had a vasectomy must agree to use highly effective birth control method(s), as defined in the protocol. True abstinence is an acceptable alternative to the use of contraception., Men must agree not to father a child or donate sperm, and WOCBP must agree not to become pregnant during the trial and for at least 12 months after the CLDN6 CAR-T infusion or CLDN6 RNA-LPX treatment., For Part 2 only: Histologically or cytologically confirmed solid tumor fulfilling inclusion criteria 1-4 that is metastatic or unresectable, and for whom there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy., Availability of a FFPE tumor tissue sample. FFPE can be from an archival tumor tissue sample, and it should be from the most recent tumor tissue obtained. If this is not available, patient must be biopsied for CLDN6 staining., Must have histological documentation of the original primary tumor via a pathology report., Must have measurable disease per RECIST 1.1 (except for germ cell tumors, where patients can be evaluated according to Cancer-Antigen (CA)-125, Alpha-fetoprotein or human chorionic gonadotropin [as applicable] or ovarian cancer, where patients can be evaluated according to CA-125. The pre-treatment sample must be at least twice the upper limit of normal)., Must have a histologically confirmed solid tumor that is metastatic or unresectable and for which there is no available standard therapy likely to confer clinical benefit, or patient who is not a candidate for such available therapy., Must be = 18 years of age at the time the pre-screening informed consent is signed., Must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the trial and are willing to participate in the trial prior to any trial-related assessments or procedures., Must have an Eastern Cooperative Oncology Group performance status of 0 to 1., Must have adequate coagulation function at screening as defined in the protocol.
排除标准
- •Has received prior CAR-T therapy, except CLDN6 CAR-T therapy., Has received vaccination with live virus vaccines within 6 weeks prior to the start of lymphodepletion (LD)., Receives concurrent systemic (oral or i.v.) steroid therapy > 10 mg prednisolone daily, or its equivalent, for an underlying condition., Has side effects of any prior therapy or procedures for any medical condition not recovered to national cancer institute common terminology criteria for adverse events (CTCAE v.5) Grade = 1.
研究者
相似试验
尚未招募
不适用
Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and in combination with other anti-cancer agents in patients with CLDN18.2-positive solid tumorsCLDN18.2-positive solid tumors / malignant tumor10072990NL-OMON53640BioNTech SE58
进行中（未招募）
1 期
A global study to evaluate preliminary efficacy of cancer drug BNT141 in patients with unresectable or metastatic CLDN18.2-positive solid tumorsCLDN18.2-positive solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10015332Term: Esophageal adenocarcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10004676Term: Biliary tract diseaseSystem Organ Class: 100000004871MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001843-25-ESBioNTech SE154
进行中（未招募）
1 期
Open-label, Dose Escalation Study of GB1275 Alone and in Combination with Anti-PD 1 Antibody in Patients with Advanced Solid Tumors or in Combination with Standard of Care with Patients with Metastatic Pancreatic Adenocarcinoma, Followed by a Dose Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Metastatic Solid TumorsPhase 1: Advanced solid tumors, metastatic pancreatic adenocarcinomaPhase 2: Specified metastatic solid tumorsEUCTR2019-001879-37-GBGB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.242
暂停
2 期
ECUR-506 in Neonatal OTC Deficiency Phase I/IIOrnithine Transcarbamylase (OTC) DeficiencyGenetic DiseasesISRCTN10957794Fortrea Development Ltd13
招募中
2 期
A clinical study of the safety and effectiveness of an investigational cell therapy given with and without an investigational RNA-based vaccine in patients with organ tumors2024-514962-38-00BioNTech Cell & Gene Therapies GmbH, BioNTech Cell & Gene Therapies GmbH145